Polymerase mutants and use with 3′-OH unblocked reversible terminators

Patent metadata

Field	Value
Publication number	US-12006519-B2
Application number	US-202318464955-A
Country	US
Kind code	B2
Filing date	Sep 11, 2023
Priority date	Jun 29, 2021
Publication date	Jun 11, 2024
Grant date	Jun 11, 2024

Abstract

Mutant polymerases are provided that have improved ability to incorporate modified nucleotides, including 3′-OH unblocked reversible terminators. The mutant polymerases may be used in a variety of applications, such as for polynucleotide sequencing, primer extension reactions, and template-independent enzymatic oligonucleotide synthesis.

First claim

What is claimed is:

1. A method for incorporating a single nucleotide into a priming strand in a template-independent reaction, the method comprising:
combining a priming strand with a 3′-OH-unmodified reversible terminator and a mutant polymerase, wherein the mutant polymerase is at least 96% identical to SEQ ID NO:2 and comprises:
a Y546H mutation at a position functionally equivalent to position 546 in Pfu polymerase;
a L409Y, L409H or L409F mutation at a position functionally equivalent to position 409 in Pfu polymerase; and
a A486X mutation at a position functionally equivalent to position 486 in Pfu polymerase, wherein X is any amino acid except alanine;

wherein incorporation of the terminator is at least 2-fold higher than for the mutant DNA polymerase of SEQ ID NO:11.

2. The method of claim 1 , wherein the polymerase further comprises one or more mutations at positions functionally equivalent to positions L270, E330, Q332, L333, P451, L453, L457, E476, L489, L490, N492, F494, Y497, and E581 in Pfu polymerase.

3. The method of 1 , wherein the 3′-OH-unmodified reversible terminator is a 2-nitrobenzyl-modified nucleotide.

4. The method of claim 1 , wherein the 3′-OH unmodified reversible terminator is a a C7- or C5-hydroxymethyl-α-tertbutyl-2-nitrobenzyl modified nucleotide and its α-thio derivative.

5. The method of claim 1 , wherein the mutant polymerase comprises the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

6. The method of claim 1 , wherein the mutant polymerase is a derivative of Pyrococcus polymerase.

7. The method of claim 1 , wherein the mutant polymerase comprises the amino acid sequence of SEQ ID NO:2.

8. The method of claim 1 , wherein the mutant polymerase is a derivative of a Thermococcus polymerase.

9. The method of claim 1 , wherein the mutant polymerase further comprises a K477W mutation at a position functionally equivalent to position 477 in Pfu polymerase.

10. The method of claim 1 , wherein the mutant polymerase comprises a mutation at a position functionally equivalent to position F494 in Pfu polymerase, wherein the mutation is F494C, F494I, F494N, or F494T.

11. A method of template-independent oligonucleotide synthesis comprising:
combining a priming strand, an 3′-OH-unmodified reversible terminator, and a mutant DNA polymerase, wherein mutant DNA polymerase comprises:
an amino acid sequences that is at least 96% identical to SEQ ID NO:2;
a Y546H mutation to histidine at a position functionally equivalent to position 546 in Pfu polymerase;
a L409Y, L409H, or L409F mutation at a position functionally equivalent to position 409 in Pfu polymerase; and
a A486X mutation at a position functionally equivalent to position 486 in Pfu polymerase, wherein X is any amino acid except alanine;

incorporating the 3′-OH-unmodified reversible terminator to the priming strand.

12. The method of claim 11 , wherein the polymerase further comprises one or more mutations at positions functionally equivalent to positions L270, E330, Q332, L333, P451, L453, L457, E476, L489, L490, N492, F494, Y497, and E581 in Pfu polymerase.

13. The method of 11 , wherein the 3′-OH-unmodified reversible terminator is a 2-nitrobenzyl-modified nucleotide.

14. The method of claim 11 , wherein the 3′-OH unmodified reversible terminator is a a C7- or C5-hydroxymethyl-a-tertbutyl-2-nitrobenzyl modified nucleotide and its α-thio derivative.

15. The method of claim 11 , wherein the mutant polymerase comprises the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

16. The method of claim 11 , wherein the mutant polymerase is a derivative of Pyrococcus polymerase.

17. The method of claim 11 , wherein the mutant polymerase comprises the amino acid sequence of SEQ ID NO:2.

18. The method of claim 11 , wherein the mutant polymerase is a derivative of a Thermococcus polymerase.

19. The method of claim 11 , wherein the mutant polymerase further comprises a K477W mutation at a position functionally equivalent to position 477 in Pfu polymerase.

20. The method of claim 11 , wherein the mutant polymerase comprises a mutation at a position functionally equivalent to position F494 in Pfu polymerase, wherein the mutation is F494C, F494I, F494N, or F494T.

Assignees

• Agilent Technologies Inc

Inventors

• Cayouette Michelle
• Fox Jeffrey
• Hansen Connie
• Hogrefe Holly
• Wu Weidong

Classifications

• C12Y207/07007

  DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

• C12Q1/6869

  Methods for sequencing · CPC title

• C12P19/34

  Polynucleotides, e.g. nucleic acids, oligoribonucleotides · CPC title

• C12Q2521/101

  DNA polymerase · CPC title

• C12Q2537/155

  Cyclic reactions · CPC title